AI English summary of an SEC filing — figures as filed
Boston Scientific BSXBoston Scientific said it entered into an Agreement and Plan of Merger with Axonics, Inc. and its wholly owned subsidiary Sadie Merger Sub, Inc. on January 8, 2024. Merger Sub will merge with and into Axonics, and Axonics will survive as a wholly owned subsidiary of the company.
Key points
AI summaryBoston Scientific said it entered into an Agreement and Plan of Merger with Axonics, Inc. and its wholly owned subsidiary Sadie Merger Sub, Inc. on January 8, 2024. Merger Sub will merge with and into Axonics, and Axonics will survive as a wholly owned subsidiary of the company.
The company said that at the effective time of the merger, each share of Axonics common stock will be converted into the right to receive $71.00 in cash, without interest. Excluded are Axonics shares held in treasury or owned by Axonics' wholly owned subsidiaries, shares owned by Boston Scientific or its wholly owned subsidiaries, and shares held by stockholders who properly exercised appraisal rights.
The company cited the conditions to closing the merger as including the affirmative vote of holders of a majority of outstanding Axonics shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, approvals from other governmental bodies, and the absence of a material adverse effect on Axonics.
The company said that under specified circumstances, Axonics will pay Boston Scientific a termination fee of $75 million, and that under certain conditions, including failure to obtain antitrust approvals, Boston Scientific will pay Axonics a termination fee of $140 million.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Axonics Merger Agreement Signed
Boston Scientific said it entered into an Agreement and Plan of Merger with Axonics, Inc. and its wholly owned subsidiary Sadie Merger Sub, Inc. on January 8, 2024. Merger Sub will merge with and into Axonics, and Axonics will survive as a wholly owned subsidiary of the company.
Source · Based on the filing body and exhibits
Cash Consideration per Axonics Share
The company said that at the effective time of the merger, each share of Axonics common stock will be converted into the right to receive $71.00 in cash, without interest. Excluded are Axonics shares held in treasury or owned by Axonics' wholly owned subsidiaries, shares owned by Boston Scientific or its wholly owned subsidiaries, and shares held by stockholders who properly exercised appraisal rights.
Source · Based on the filing body and exhibits
Conditions to Closing the Merger
The company cited the conditions to closing the merger as including the affirmative vote of holders of a majority of outstanding Axonics shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, approvals from other governmental bodies, and the absence of a material adverse effect on Axonics.
Source · Based on the filing body and exhibits
Mutual Termination Fee Terms
The company said that under specified circumstances, Axonics will pay Boston Scientific a termination fee of $75 million, and that under certain conditions, including failure to obtain antitrust approvals, Boston Scientific will pay Axonics a termination fee of $140 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…